Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06101862
Other study ID # H-23024848
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date October 1, 2036

Study information

Verified date October 2023
Source Herlev and Gentofte Hospital
Contact Niels Thue Olsen, PhD
Phone +45 38 68 38 68
Email niels.thue.olsen@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Coronary computed tomography angiography (CCTA) is a widely accepted initial diagnostic test for individuals suspected of having chronic coronary syndromes. However, there is limited evidence supporting its use in the acute setting. So far, no large-scale randomized trial has examined the performance of CCTA as an alternative to invasive coronary angiography (ICA) in individuals with non-ST-segment elevation myocardial infarction (NSTEACS). If CCTA were to replace ICA as a routine procedure for individuals with NSTEACS, it could reduce the risk of complications related to ICA, improve patient comfort, expedite decision-making, and reduce healthcare expenses and interhospital transfers.


Recruitment information / eligibility

Status Recruiting
Enrollment 2300
Est. completion date October 1, 2036
Est. primary completion date October 1, 2026
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria: - Admitted with non-ST-segment elevation myocardial infarction or unstable angina pectoris and an indication for subacute ICA - Elevated troponin or ischemic electrocardiographic changes - Written informed consent Exclusion criteria: - Instability requiring acute or emergent ICA - History of percutaneous coronary intervention or coronary artery bypass grafting - Estimated glomerular filtration rate < 30 mL/min/1.73m2 - Expected poor quality of the CCTA - Prior CCTA or ICA during index admission or within 1 week - Known allergy to beta-blockers or contrast agent - Pregnant or nursing - Previously randomized in this trial

Study Design


Intervention

Procedure:
CCTA
Participants will be examined during admission.
Conventional ICA
Standard-of-care with conventional ICA.
Other:
Team-based interventional triage
If the CCTA suggests a potential requirement for revascularization, the CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.

Locations

Country Name City State
Denmark Herlev and Gentofte Hospital Copenhagen Hellerup

Sponsors (7)

Lead Sponsor Collaborator
Herlev and Gentofte Hospital Amager Hospital, Bispebjerg Hospital, Hvidovre University Hospital, North Zealand Hospital, Denmark, Rigshospitalet, Denmark, Zealand University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with a combined endpoint of major adverse cardiac events All-cause mortality, non-fatal myocardial infarction, hospitalization with refractory angina, or hospitalization with heart failure. At 1 year.
Secondary Number of participants with a combined endpoint of major adverse cardiac events All-cause mortality, non-fatal myocardial infarction, hospitalization with refractory angina, or hospitalization with heart failure. At 1st hospital discharge, an average of 2 days, and at 30 days.
Secondary Number of participants with all-cause mortality At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with non-fatal myocardial infarction At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with hospitalization with refractory angina At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with hospitalization with heart failure. At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with stroke At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with cardiovascular death At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with serious adverse events At 1st hospital discharge, an average of 2 days.
Secondary Number of participants with procedure-related complications At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with bleeding according to Bleeding Academic Research Consortium At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with coronary revascularization At 1st hospital discharge, an average of 2 days, at 30 days, and at 1 year.
Secondary Number of participants with hospitalization for any cardiac reason or related to cardiovascular treatment At 1 year
Secondary Number of participants with any invasive or non-invasive examination for ischemic heart disease At 1st hospital discharge, an average of 2 day, and at 1 year.
Secondary Costs of index admission, cardiovascular visits and admissions, and procedures At 1 year.
Secondary Angina symptom burden Measured by Seattle Angina Questionnaire At 1 year.
Secondary Health-related Quality of life Measured by EQ-5D-5L At 1 year.
Secondary Length of index hospitalization At 1st hospital discharge, an average of 2 days.
Secondary Time from index hospitalization to examination At examination, an average of 1 day.
Secondary Radiation dosage of all cardiac diagnostic examinations and interventions At 1st hospital discharge, an average of 2 days, and at 1 year.
Secondary Fluoroscopy time At 1st hospital discharge, an average of 2 days.
Secondary Procedure time At 1st hospital discharge, an average of 2 days.
Secondary Contrast use At 1st hospital discharge, an average of 2 days.
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02759406 - Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A